FDA Has "Legal Recourse" To Force Rx-To-OTC Switch Of Antihistamines
Executive Summary
FDA has the authority to switch prescription products to over-the-counter status and could resort to legal remedies if the switch is opposed by the drugs' manufacturers, Center for Drug Evaluation & Research Director Janet Woodcock, MD, told a House panel June 13.
You may also be interested in...
Pfizer Zyrtec-D Labeled "Rx-only" Pending Antihistamine OTC Switch Decision
Pfizer's antihistamine/decongestant combination product Zyrtec-D has been approved as "Rx-only" pending decision on over-the-counter switch status of the antihistamine class.
Pfizer Zyrtec-D Labeled "Rx-only" Pending Antihistamine OTC Switch Decision
Pfizer's antihistamine/decongestant combination product Zyrtec-D has been approved as "Rx-only" pending decision on over-the-counter switch status of the antihistamine class.
Antihistamine OTC Switch Moves To Legal Arena After Committee Votes
The potential OTC switch of the antihistamines Claritin, Allegra and Zyrtec will move into the legal arena following a review by FDA's Nonprescription and Pulmonary-Allergy Drugs Advisory Committees May 11.